Altium Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Altium Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$591K	Buy	+999	New	+$649K	0.04%	212

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Altium Wealth Management's REGN Position: Q2 2022 in Review

Altium Wealth Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2022: 999 shares worth $591K. The stake represents 0.04% of the portfolio and ranks #212 among its holdings.

1,063 funds tracked by Wall St. Rank hold REGN as of Q2 2022.

Altium Wealth Management held 999 shares of Regeneron Pharmaceuticals worth $591K as of Q2 2022.
Regeneron Pharmaceuticals was a new Altium Wealth Management position in Q2 2022.
Regeneron Pharmaceuticals made up 0.04% of Altium Wealth Management's portfolio in Q2 2022, its #212 holding.
1,063 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.

Based on Altium Wealth Management's 13F filing for Q2 2022, filed 22 Jul 2022.